In a significant boost for the European medical technology landscape, Milan-based neuro-tech innovator WISE has successfully concluded its oversubscribed Series D financing round, securing €30 million ($34.8 million). This infusion of capital represents a pivotal milestone for the company as it seeks to disrupt the spinal cord stimulation (SCS) market—a sector currently experiencing rapid expansion within the global neurology devices landscape.
The funding round was bolstered by the participation of ENEA Tech and Biomedical, an Italian foundation dedicated to accelerating innovation and technology transfer in the life sciences. Beyond the financial commitment, ENEA Tech and Biomedical has entered into a strategic partnership with WISE, signaling a broader commitment to maturing high-potential Italian medical technologies for the global market.
Main Facts: The Heron Lead and the Future of Chronic Pain Management
At the heart of WISE’s growth strategy is the "Heron" lead, a next-generation spinal cord stimulation device designed to redefine how clinicians approach chronic pain management. The Heron lead utilizes a proprietary, minimally invasive percutaneous implant technique, aiming to bridge the gap between surgical efficacy and patient comfort.
Unlike traditional systems, the Heron lead is engineered to provide highly targeted, directional stimulation. By leveraging a unique combination of therapeutic surgical paddle-style leads and cylindrical leads, the device offers a hybrid approach that allows for greater precision. According to internal data provided by WISE, this dual-architecture design enhances energy efficiency and significantly improves neural signal sensing, allowing for more adaptive and responsive pain therapy.
The €30 million injection completes a total Series D effort that began in June 2024, when the company raised an initial €25 million, supported by a venture debt facility from the European Investment Bank (EIB). This total capital pool is earmarked for the comprehensive development, regulatory certification, and initial clinical validation of the Heron platform.
Chronology: A Path from Laboratory to Market
The evolution of WISE from a research-focused entity to a commercial-stage contender has been marked by methodical development and strategic milestones:
- 2022: The company achieved a significant regulatory win with the FDA clearance of its WISE Cortical Strip (WCS), a soft electrode designed for neurophysiological monitoring during complex surgeries such as epilepsy resection and brain tumor removal.
- June 2024: WISE initiated its Series D financing round, raising €25 million. This round was notable for the inclusion of the European Investment Bank, providing the company with the financial runway to scale its manufacturing and R&D operations.
- July 2025: The WCS electrode received the CE mark under the European Union’s rigorous Medical Device Regulation (EU MDR), validating the company’s commitment to European safety and performance standards.
- June 2026: The successful final close of the Series D round, totaling an additional €30 million, brings total funding to a level sufficient to transition the Heron lead from the bench to the bedside.
Supporting Data: The Neurology Market Landscape
The timing of WISE’s financing aligns with a broader surge in the neurology devices market. According to comprehensive analysis by GlobalData, the global neurology devices sector is projected to reach a valuation exceeding $24.2 billion by 2035. Within this space, Spinal Cord Stimulation remains one of the most dynamic and competitive segments.
Current market dynamics are defined by high-intensity competition. As of 2025, industry titan Medtronic continues to command a dominant position, holding approximately 29.8% of the US rechargeable SCS market. However, the entry of agile innovators like WISE, which offer differentiated, minimally invasive technologies, suggests that the market is ripe for disruption.
The clinical need remains profound. Chronic pain affects hundreds of millions of people globally, and the failure of traditional pharmacological interventions has driven a shift toward neuromodulation. The challenge for new entrants like WISE is not just technical performance, but also the integration of their devices into existing surgical workflows—a hurdle the Heron lead specifically addresses through its percutaneous design.
Official Responses and Strategic Vision
Luca Varagnan, CEO of WISE, framed the recent financing as the "final push" required to realize the company’s clinical ambitions. "With the Heron lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need," Varagnan stated. "This financing gives us the resources to complete the journey from bench to bedside."
The partnership with ENEA Tech and Biomedical is viewed as a validation of the Italian biomedical ecosystem. By combining private capital with strategic institutional support, WISE is positioned to navigate the complex regulatory pathways required for both the Heron lead and its broader electrode portfolio.
The company has explicitly stated that while the Heron lead is the primary focus, a portion of the proceeds will be utilized to expand the clinical footprint of its existing electrode portfolio. This includes furthering the adoption of the WISE Cortical Strip, which has already established a reputation for safety and efficacy in the intraoperative neuro-monitoring space.
Implications: Changing the Paradigm of Neuromodulation
The implications of WISE’s recent success extend far beyond the company’s balance sheet.
1. The Shift to Minimally Invasive Procedures
The medical community has been steadily moving toward minimally invasive surgery (MIS) to reduce recovery times, infection risks, and surgical trauma. By utilizing a percutaneous approach for a lead that offers the benefits of a surgical paddle, WISE is effectively addressing a "best of both worlds" scenario. If clinical trials confirm the efficacy of the Heron lead, it could become the new gold standard for patients who require advanced stimulation but are not ideal candidates for invasive laminectomy procedures.
2. Strengthening the European MedTech Hub
The involvement of the EIB and ENEA Tech and Biomedical highlights the strategic importance of the European medical technology sector. As regulatory environments become more stringent under the EU MDR, well-funded companies like WISE serve as proof that European startups can successfully navigate these challenges to compete with US-based incumbents.
3. Future-Proofing Pain Management
As the population ages, the prevalence of chronic pain conditions is expected to rise. The ability to monitor neural signals more accurately—a key feature of the Heron lead—opens the door to "closed-loop" stimulation. In a closed-loop system, the device doesn’t just deliver a constant stream of pulses; it monitors the patient’s neural response and adjusts the stimulation in real-time. This level of sophistication is the "Holy Grail" of neuromodulation, and WISE’s current development trajectory suggests they are well-positioned to contribute to this evolution.
Conclusion: The Path Ahead
The road ahead for WISE involves the rigorous process of regulatory certification and the launch of first-in-human clinical studies for the Heron lead. These studies will be the ultimate test of the device’s design philosophy. If the Heron lead performs as predicted in human subjects, it will likely capture significant market share by offering surgeons a tool that is both easier to implant and more effective at delivering therapeutic stimulation.
For investors and clinicians alike, the WISE story is one to watch. In a field dominated by large-scale legacy players, the success of a focused, technology-forward company like WISE underscores the enduring power of innovation in the neurology space. As the company transitions from the funding stage to the clinical implementation stage, the medical community waits to see if the Heron lead will indeed herald a new era in the treatment of chronic pain.
About the Author
